Page 1 | Search Results | Blood | American Society of Hematology

1-15 of 15

Sort by

Sort Order Select

Journal Articles

Incidence of Breakthrough Fungal Infections in Acute Myeloid Leukemia Patients Receiving Low Intensity Therapy in the Upfront and Relapsed/Refractory Setting

Kaci Shuman, Rebecca Garcia Hunt, Maho Hibino, Tyler Stone, Sarah Dralle, Megan Manuel, Susan Lyerly, Leslie Renee Ellis, Rupali Bhave, Timothy S. Pardee, Bayard L. Powell, Daniel R. Reed

Blood (2021) 138 (Supplement 1): 3372.

https://doi.org/10.1182/blood-2021-146620

Published: 2021

Journal Articles

Frontline Selinexor and Chemotherapy Is Highly Active in Older Adults with Acute Myeloid Leukemia (AML)

Timothy S. Pardee, MDPhD, Kristin M. Pladna, M.S., Susan Lyerly, P.A.-C., Sarah Dralle, Megan Manuel, NP, Leslie Renee Ellis, MD MSHPEd, Dianna S. Howard, MD, Rupali Bhave, MD, Bayard L. Powell, MD

Blood (2020) 136 (Supplement 1): 24–25.

https://doi.org/10.1182/blood-2020-139999

Published: 2020

Journal Articles

Evaluating the Utilization of All- T rans Retinoic Acid and Arsenic Trioxide during Consolidation Therapy for Patients Receiving Treatment for Acute Promyelocytic Leukemia

Laura A Bowers, PharmD, Maho Hibino, PharmD, Rebecca Garcia Hunt, PharmD, Leslie Renee Ellis, MD, Rupali Bhave, MD, Dianna S. Howard, MD, Susan Lyerly, P.A.-C., Sarah Dralle, NP, Megan Manuel, NP, Timothy S. Pardee, MD PhD, Bayard L Powell, MD

Blood (2019) 134 (Supplement_1): 3901.

https://doi.org/10.1182/blood-2019-131817

Published: 2019

Journal Articles

Assessing Efficacy and Safety of Daunorubicin and Cytarabine Liposomal in Patients with Acute Myeloid Leukemia

Elizabeth Rogers, PharmD, MPH, Maho Hibino, PharmD, Rebecca Garcia Hunt, PharmD, Leslie Renee Ellis, MD, Rupali Bhave, MD, Dianna S. Howard, MD, Susan Lyerly, P.A.-C., Sarah Dralle, NP, Megan Manuel, NP, Timothy S. Pardee, MD PhD, Bayard L Powell, MD

Blood (2019) 134 (Supplement_1): 5134.

https://doi.org/10.1182/blood-2019-131328

Published: 2019

Journal Articles

Selinexor in Combination with Induction and Consolidation Therapy in Older Adults with AML Is Highly Active

Timothy S. Pardee, MD PhD, Kris C Wood, PhD, Kevin H Lin, BS, Justine Rutter, PhD, Mariaelena Pierobon, MD, Emanuel Petricoin, PhD, Susan Lyerly, P.A.-C., Sarah Dralle, NP, Megan Manuel, NP, Leslie Renee Ellis, MD, Dianna S. Howard, MD, Rupali Bhave, MD, Bayard L Powell, MD

Blood (2019) 134 (Supplement_1): 1388.

https://doi.org/10.1182/blood-2019-129413

Published: 2019

Journal Articles

Therapeutic Manipulation of Cancer Cell Metabolism with the Mitochondrial Metabolism Inhibitor Cpi-613 in Addition to Chemotherapy Abrogates the Adverse Prognostic Effect of Age in Relapsed and Refractory AML

Timothy Pardee, MDPhD, Scott Isom, M.S., Leslie Renee Ellis, MD MSHPEd, Dianna S. Howard, MD, Rupali Bhave, MD, Megan Manuel, M.S.N, Sarah Dralle, M.S.N., Susan Lyerly, P.A.-C., Bayard L. Powell, MD

Blood (2018) 132 (Supplement 1): 1355.

https://doi.org/10.1182/blood-2018-99-118991

Published: 2018

Journal Articles

Incidence of Bleeding Events in Acute Myeloid Leukemia (AML) Patients Receiving Anticoagulation Therapy for Treatment of Deep Vein Thrombosis (DVT) or Pulmonary Embolism (PE) Who Are Also Undergoing Induction or Re-Induction Therapy

Meagan Scott, PharmD, Maho Hibino, PharmD, Marie Cavalier, PharmD, Bayard L. Powell, MD, Dianna S. Howard, MD, Leslie Renee Ellis, MD, Rupali Bhave, MD, Susan Lyerly, P.A.-C., Megan Manuel, M.S.N, Sarah Dralle, M.S.N., Timothy S Pardee, MD PhD

Blood (2017) 130 (Supplement 1): 2091.

https://doi.org/10.1182/blood.V130.Suppl_1.2091.2091

Published: 2017

Journal Articles

Interim Analysis of a Single Arm Phase II Study of Cpi-613 in Combination with High Dose Cytarabine and Mitoxantrone for Patients with Relapsed or Refractory AML

Timothy S Pardee, MD PhD, Scott Isom, M.S., Leslie Renee Ellis, MD, Dianna S. Howard, MD, Rupali Bhave, MD, Megan Manuel, M.S.N, Sarah Dralle, M.S.N., Susan Lyerly, P.A.-C., Bayard L. Powell, MD

Blood (2017) 130 (Supplement 1): 2626.

https://doi.org/10.1182/blood.V130.Suppl_1.2626.2626

Published: 2017

Journal Articles

Outcomes of Adult Patients with Acute Lymphoblastic Leukemia Treated with a Modified CALGB 10102 Regimen in a Real World Setting

Margaux Wooster, B.S., Scott Isom, M.S., Leslie Renee Ellis, MD, Dianna S. Howard, MD, Megan Manuel, M.S.N, Rupali Bhave, MD, Sarah Dralle, M.S.N., Susan Lyerly, P.A.-C., Bayard L. Powell, MD, Timothy S Pardee, MD PhD

Blood (2017) 130 (Supplement 1): 5044.

https://doi.org/10.1182/blood.V130.Suppl_1.5044.5044

Published: 2017

Journal Articles

TCA Cycle Inhibition By Cpi-613 Increases Sensitivity to Chemotherapy in Older and Poor Risk Acute Myeloid Leukemia (AML)

Timothy S Pardee, MD PhD, Lance D Miller, PhD, Kristin Pladna, MS, Scott Isom, MS, Leslie Renee Ellis, MD, Dmitriy Berenzon, MD, Dianna Howard, MD, Megan Manuel, MSN, Sarah Dralle, MSN, Susan Lyerly, PA-C, Bayard L Powell, MD

Blood (2016) 128 (22): 4062.

https://doi.org/10.1182/blood.V128.22.4062.4062

Published: 2016

Journal Articles

The Mitochondrial Metabolism Inhibitor Cpi-613 in Combination with High Dose Ara-C (HDAC) and Mitoxantrone Is Highly Active in Poor Risk Relapsed or Refractory Acute Myeloid Leukemia (AML)

Timothy Pardee, MD PhD, Kristin Pladna, MS, Scott Isom, MS, Leslie Renee Ellis, MD, Dmitriy Berenzon, MD, Dianna Howard, MD, Megan Manuel, MSN, Sarah Dralle, MSN, David D Hurd, MD, Susan Lyerly, PA-C, Bayard L Powell, MD

Blood (2015) 126 (23): 2556.

https://doi.org/10.1182/blood.V126.23.2556.2556

Published: 2015

Journal Articles

The Mitochondrial Metabolism Inhibitor Cpi-613 Is Highly Active in Combination with High Dose Ara-C (HiDAC) and Mitoxantrone in a Phase I Study for Relapsed or Refractory Acute Myeloid Leukemia (AML)

Timothy S Pardee, MD PhD, Kristin Stadelman, MS, Scott Isom, MS, Leslie Renee Ellis, MD, Dmitriy Berenzon, MD, David D Hurd, MD, Robin Harrelson, BSN, Megan Manuel, MSN, Sarah Dralle, MSN, Susan Lyerly, PA, Bayard L. Powell, MD

Blood (2014) 124 (21): 3744.

https://doi.org/10.1182/blood.V124.21.3744.3744

Published: 2014

Journal Articles

High Dose Cytarabine, Mitoxantrone and L-Asparaginase (HAMA) Salvage For Relapsed Or Refractory Acute Myeloid Leukemia (AML) In The Elderly

Tamjeed Ahmed, MD, Scott Holwerda, MD, Timothy Pardee, MD, PhD, Scott Isom, MS, Susan Lyerly, PA, Leslie Renee Ellis, MD, Megan Manuel, MSN, Sarah Dralle, MSN, Berenzon Dmitriy, MD, Heidi D. Klepin, MD, MS, Bayard L. Powell, MD

Blood (2013) 122 (21): 2700.

https://doi.org/10.1182/blood.V122.21.2700.2700

Published: 2013

Journal Articles

A Phase I Study Of The Safety, Efficacy and Pharmacokinetics Of The First In Class Pyruvate Dehydrogenase Complex Inhibitor Cpi-613 In Patients With Advanced Hematologic Malignancies

Timothy Pardee, MD, PhD, King Lee, PhD, RAC, John Luddy, MS, Claudia Maturo, MS, Robert Rodriguez, BSc, MBA, Denise A Levitan, MD, David D Hurd, MD, Leslie Renee Ellis, MD, Scott Isom, MS, Robin Harrelson, BSN, Megan Manuel, MSN, Sarah Dralle, MSN, Susan Lyerly, PA, Bayard L. Powell, MD

Blood (2013) 122 (21): 486.

https://doi.org/10.1182/blood.V122.21.486.486

Published: 2013

Journal Articles

High Dose Cytarabine and Clofarabine (HiDAC → CLOF) in Relapsed or Refractory Acute Myeloid Leukemia, a Phase 2 Trial.

Bayard Powell, Ralph D’Agostino, Jr., PhD, Denise Levitan, MD, Leslie Renee Ellis, MD, Susan Lyerly, PA-C, Megan Skiles, PA-C, Megan Manuel, NP, Robin Harrelson, RN, Claire Kimbrough, David Duane Hurd, MD

Blood (2008) 112 (11): 1936.

https://doi.org/10.1182/blood.V112.11.1936.1936

Published: 2008

NARROW

Incidence of Breakthrough Fungal Infections in Acute Myeloid Leukemia Patients Receiving Low Intensity Therapy in the Upfront and Relapsed/Refractory Setting

Frontline Selinexor and Chemotherapy Is Highly Active in Older Adults with Acute Myeloid Leukemia (AML)

Evaluating the Utilization of All- T rans Retinoic Acid and Arsenic Trioxide during Consolidation Therapy for Patients Receiving Treatment for Acute Promyelocytic Leukemia

Assessing Efficacy and Safety of Daunorubicin and Cytarabine Liposomal in Patients with Acute Myeloid Leukemia

Selinexor in Combination with Induction and Consolidation Therapy in Older Adults with AML Is Highly Active

Therapeutic Manipulation of Cancer Cell Metabolism with the Mitochondrial Metabolism Inhibitor Cpi-613 in Addition to Chemotherapy Abrogates the Adverse Prognostic Effect of Age in Relapsed and Refractory AML

Incidence of Bleeding Events in Acute Myeloid Leukemia (AML) Patients Receiving Anticoagulation Therapy for Treatment of Deep Vein Thrombosis (DVT) or Pulmonary Embolism (PE) Who Are Also Undergoing Induction or Re-Induction Therapy

Interim Analysis of a Single Arm Phase II Study of Cpi-613 in Combination with High Dose Cytarabine and Mitoxantrone for Patients with Relapsed or Refractory AML

Outcomes of Adult Patients with Acute Lymphoblastic Leukemia Treated with a Modified CALGB 10102 Regimen in a Real World Setting

TCA Cycle Inhibition By Cpi-613 Increases Sensitivity to Chemotherapy in Older and Poor Risk Acute Myeloid Leukemia (AML)

The Mitochondrial Metabolism Inhibitor Cpi-613 in Combination with High Dose Ara-C (HDAC) and Mitoxantrone Is Highly Active in Poor Risk Relapsed or Refractory Acute Myeloid Leukemia (AML)

The Mitochondrial Metabolism Inhibitor Cpi-613 Is Highly Active in Combination with High Dose Ara-C (HiDAC) and Mitoxantrone in a Phase I Study for Relapsed or Refractory Acute Myeloid Leukemia (AML)

High Dose Cytarabine, Mitoxantrone and L-Asparaginase (HAMA) Salvage For Relapsed Or Refractory Acute Myeloid Leukemia (AML) In The Elderly

A Phase I Study Of The Safety, Efficacy and Pharmacokinetics Of The First In Class Pyruvate Dehydrogenase Complex Inhibitor Cpi-613 In Patients With Advanced Hematologic Malignancies

High Dose Cytarabine and Clofarabine (HiDAC → CLOF) in Relapsed or Refractory Acute Myeloid Leukemia, a Phase 2 Trial.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only